Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 26, 2021; 9(24): 7146-7153
Published online Aug 26, 2021. doi: 10.12998/wjcc.v9.i24.7146
Published online Aug 26, 2021. doi: 10.12998/wjcc.v9.i24.7146
S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report
Xin Wang, Beijing University of Chinese Medicine; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China
Yan-Fen Shi, Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China
Jiang-Hui Duan, Department of Radiology, China-Japan Friendship Hospital, Beijing 100029, China
Chao Wang, Huang-Ying Tan, Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China
Author contributions: Wang X reviewed the literature and contributed to manuscript drafting; Shi YF provided pathological information; Duan JH analyzed and interpreted the imaging findings; Wang C contributed to data collection; Tan HY was responsible for the revision of the manuscript; all authors have read and approved the final version of the manuscript.
Informed consent statement: This patient provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have no conflicts of interest to report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Huang-Ying Tan, MD, PhD, Chief Physician, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuadong Street, Beijing 100029, China. tanhuangying@263.net
Received: January 4, 2021
Peer-review started: January 4, 2021
First decision: April 25, 2021
Revised: April 27, 2021
Accepted: July 6, 2021
Article in press: July 6, 2021
Published online: August 26, 2021
Peer-review started: January 4, 2021
First decision: April 25, 2021
Revised: April 27, 2021
Accepted: July 6, 2021
Article in press: July 6, 2021
Published online: August 26, 2021
Core Tip
Core Tip: Neuroendocrine carcinoma of the breast (NECB) is a highly malignant tumor. There is no standard treatment protocol for NECB due to its rarity. We treated an NECB patient with the S-1 combined with temozolomide (STEM) regimen as a second-line treatment due to disease progression. The effect of the STEM regimen on the patient was good, and she achieved a progression-free survival of 23 mo. During the chemotherapy period, the patient achieved a partial response and suffered only grade 1 adverse reactions. This report can serve as a reference for clinical practice.